252(top 100%)
PR articles
47.5K(top 1%)
PR citations
77(top 100%)
PR h-index
82(top 100%)
h-index
274
documents
58.8K
doc citations
5.7K
citing journals
100
times ranked

Publications

255 PR articles • 49,637 PR citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1Diabetes Risk Factors and Bone Microarchitecture as Assessed by High-Resolution Peripheral Quantitative Computed Tomography in Adults With Long-standing Type 1 Diabetes
Diabetes Care, 2024, 47, 1548-1558
6.210Citations (PDF)
2Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial
Diabetes Care, 2024, 47, 562-570
6.210Citations (PDF)
3Neuropathic Pain With and Without Diabetic Peripheral Neuropathy in Type 1 Diabetes
Diabetes Care, 2024, 47, 1559-1567
6.210Citations (PDF)
4Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes
Diabetes, 2024, 73, 823-833
4.224Citations (PDF)
5Epicardial and intra-thoracic adipose tissue and cardiovascular calcifications in type 1 diabetes (T1D) in epidemiology of diabetes Interventions and Complications (EDIC): A pilot study
American Journal of Preventive Cardiology, 2024, 18, 100650
2.80Citations (PDF)
6History of the Diabetes Control and Complications Trial and Its Follow-up Epidemiology of Diabetes Interventions and Complications Study: Studies That Changed the Treatment of Type 1 Diabetes
Diabetes Care, 2024, 47, 1511-1517
6.26Citations (PDF)
7Relationship Between Average Glucose Levels and HbA1c Differs Across Racial Groups: A Substudy of the GRADE Randomized Trial
Diabetes Care, 2024, 47, 2155-2163
6.27Citations (PDF)
8Glycemia reduction in type 2 diabetes—Hypoglycemia outcomes: A randomized clinical trial
PLoS ONE, 2024, 19, e0309907
2.32Citations (PDF)
9Relationships Between the Cumulative Incidences of Long-term Complications in Type 1 Diabetes: The DCCT/EDIC Study
Diabetes Care, 2023, 46, 361-368
6.217Citations (PDF)
10Response to Comment on Lachin et al. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes Care 2022;45:2445–2448
Diabetes Care, 2023, 46, e13-e13
6.22Citations (PDF)
11CKD Associates with Cognitive Decline in Middle-Aged and Older Adults with Long-Standing Type 1 Diabetes
Kidney360, 2023, 4, 1058-1071
1.92Citations (PDF)
12Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients
Journal of Diabetes Investigation, 2022, 13, 125-133
2.742Citations (PDF)
13Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes
Diabetes Care, 2022, 45, 585-593
6.25Citations (PDF)
14Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study
Diabetes Care, 2022, 45, 659-665
6.228Citations (PDF)
15Biochemical Markers of Bone Turnover in Older Adults With Type 1 Diabetes
Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2405-e2416
4.121Citations (PDF)
16Left Ventricular Structure, Tissue Composition, and Aortic Distensibility in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications
American Journal of Cardiology, 2022, 174, 158-165
1.82Citations (PDF)
17Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study
Lancet Diabetes and Endocrinology,the, 2022, 10, 509-518
21.841Citations (PDF)
18Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study
Diabetes Care, 2022, 45, 1779-1787
6.225Citations (PDF)
19Physical Function in Middle-aged and Older Adults With Type 1 Diabetes: Long-term Follow-up of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Diabetes Care, 2022, 45, 2037-2045
6.211Citations (PDF)
20Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial
Diabetes Care, 2022, 45, 2445-2448
6.213Citations (PDF)
21Cardiometabolic Risk Factors and Incident Cardiovascular Disease Events in Women vs Men With Type 1 Diabetes
JAMA Network Open, 2022, 5, e2230710
6.640Citations (PDF)
22Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes
Diabetes Care, 2022, 45, 2943-2949
6.24Citations (PDF)
23Refractive Error and Retinopathy Outcomes in Type 1 Diabetes
Ophthalmology, 2021, 128, 554-560
7.813Citations (PDF)
24Moderation of the effect of glycemia on the risk of cardiovascular disease in type 1 diabetes: The DCCT/EDIC study
Diabetes Research and Clinical Practice, 2021, 171, 108591
5.914Citations (PDF)
25Association of Baseline Characteristics With Insulin Sensitivity and β-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort
Diabetes Care, 2021, 44, 340-349
6.219Citations (PDF)
26OGTT Glucose Response Curves, Insulin Sensitivity, and β-Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve β-Cell Function
Diabetes Care, 2021, 44, 817-825
6.240Citations (PDF)
27Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia
Journal of Clinical Investigation, 2021, 131,
10.673Citations (PDF)
28Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study
Diabetes Care, 2021, 44, 1309-1316
6.28Citations (PDF)
29Cost‐efficient clinical studies with continuous time survival outcomes
Statistics in Medicine, 2021, 40, 3682-3694
1.71Citations (PDF)
30Association of glycemia with insulin sensitivity and β-cell function in adults with early type 2 diabetes on metformin alone
Journal of Diabetes and Its Complications, 2021, 35, 107912
2.48Citations (PDF)
31Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes
Diabetes Care, 2021, 44, 1499-1505
6.233Citations (PDF)
32Hyperglucagonemia Does Not Explain the β-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study
Diabetes Care, 2021, 44, 1961-1969
6.218Citations (PDF)
33Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study
Lancet Diabetes and Endocrinology,the, 2021, 9, 436-445
21.8113Citations (PDF)
34Serum urate and cardiovascular events in the DCCT/EDIC study
Scientific Reports, 2021, 11,
3.47Citations (PDF)
35The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes
Diabetes Care, 2021, 44, 2225-2230
6.248Citations (PDF)
36Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
ESC Heart Failure, 2021, 8, 4517-4527
3.273Citations (PDF)
37Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies
PLoS ONE, 2021, 16, e0257154
2.316Citations (PDF)
38Coronary Artery Disease Events and Carotid Intima‐Media Thickness in Type 1 Diabetes in the DCCT/EDIC Cohort
Journal of the American Heart Association, 2021, 10,
4.013Citations (PDF)
39Closed testing of each group versus the others combined in a multiple group analysis
Clinical Trials, 2020, 17, 77-86
1.83Citations (PDF)
40Withdrawal of medications leads to worsening of <scp>OGTT</scp> parameters in youth with impaired glucose tolerance or <scp>recently‐diagnosed</scp> type 2 diabetes
Pediatric Diabetes, 2020, 21, 1437-1446
5.58Citations (PDF)
41Worst-Rank Score Methods—A Nonparametric Approach to Informatively Missing Data
JAMA - Journal of the American Medical Association, 2020, 324, 1670
16.66Citations (PDF)
42DNA methylation mediates development of HbA1c-associated complications in type 1 diabetes
Nature Metabolism, 2020, 2, 744-762
17.182Citations (PDF)
43An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study
Diabetes Care, 2020, 43, 2478-2484
6.224Citations (PDF)
44Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC
Diabetes, 2020, 69, 2440-2445
4.25Citations (PDF)
45The minimum intensity of a mixed exposure that increases the risk of an outcome
Statistics in Medicine, 2020, 39, 4016-4024
1.70Citations (PDF)
46Nonparametric Statistical Analysis
JAMA - Journal of the American Medical Association, 2020, 323, 2080
16.623Citations (PDF)
47Models to Assess the Association of a Semiquantitative Exposure With Outcomes
American Journal of Epidemiology, 2020, 189, 1573-1582
3.33Citations (PDF)
48Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 2020;69:291–299
Diabetes, 2020, 69, e7-e8
4.23Citations (PDF)
49Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study
Diabetes, 2020, 69, 1000-1010
4.2186Citations (PDF)
50Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study
Diabetes Care, 2020, 43, 867-874
6.282Citations (PDF)
51Risk Factors for Hearing Impairment in Type 1 Diabetes
Endocrine Practice, 2019, 25, 1243-1254
3.310Citations (PDF)
52Closed testing using surrogate hypotheses with restricted alternatives
PLoS ONE, 2019, 14, e0219520
2.33Citations (PDF)
53Immune Complexes and the Risk of CVD in Type 1 Diabetes
Diabetes, 2019, 68, 1853-1860
4.218Citations (PDF)
54Association of Habitual Daily Physical Activity With Glucose Tolerance and β-Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study
Diabetes Care, 2019, 42, 1521-1529
6.214Citations (PDF)
55Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes
Diabetes Care, 2019, 42, 1742-1751
6.267Citations (PDF)
56Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study
Diabetes Care, 2019, 42, 1284-1289
6.256Citations (PDF)
57Risk Factors for Kidney Disease in Type 1 Diabetes
Diabetes Care, 2019, 42, 883-890
6.2116Citations (PDF)
58Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study
Diabetes Care, 2019, 42, 875-882
6.2172Citations (PDF)
59The Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes
JACC: Cardiovascular Imaging, 2019, 12, 1341-1349
6.269Citations (PDF)
60Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study
Diabetes Care, 2019, 42, 657-664
6.240Citations (PDF)
61Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657–664
Diabetes Care, 2019, 42, e137-e137
6.21Citations (PDF)
62Mediation of the association of smoking and microvascular complications by glycemic control in type 1 diabetes
PLoS ONE, 2019, 14, e0210367
2.323Citations (PDF)
63Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
Lancet Diabetes and Endocrinology,the, 2019, 7, 128-139
21.8322Citations (PDF)
64Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
European Heart Journal, 2018, 39, 363-370
2.2227Citations (PDF)
65Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype
Diabetes Care, 2018, 41, 596-603
6.265Citations (PDF)
66Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study
Journal of the American Heart Association, 2018, 7,
4.09Citations (PDF)
67Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. Diabetes Care 2017;40:655–662
Diabetes Care, 2018, 41, e64-e64
6.23Citations (PDF)
68Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Circulation, 2018, 137, 119-129
18.1413Citations (PDF)
69How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Diabetes Care, 2018, 41, 356-363
6.2623Citations (PDF)
70Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease
Circulation, 2018, 138, 1599-1601
18.136Citations (PDF)
71Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort
Diabetes Care, 2018, 41, 2495-2501
6.239Citations (PDF)
72Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes
Diabetes Care, 2018, 41, 1717-1725
6.2155Citations (PDF)
73Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp
Diabetes Care, 2018, 41, 1696-1706
6.2153Citations (PDF)
74The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC)
Journal of Diabetes and Its Complications, 2018, 32, 934-939
2.415Citations (PDF)
75Properties of composite time to first event versus joint marginal analyses of multiple outcomes
Statistics in Medicine, 2018, 37, 3918-3930
1.76Citations (PDF)
76What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?
Journal of Diabetes and Its Complications, 2018, 32, 911-915
2.436Citations (PDF)
77Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes
Diabetes Care, 2018, 41, 1917-1925
6.2166Citations (PDF)
78A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk
Diabetes Care, 2018, 41, 1887-1894
6.2151Citations (PDF)
79Optimal screening schedules for disease progression with application to diabetic retinopathy
Biostatistics, 2018, 19, 1-13
2.116Citations (PDF)
80Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial
Diabetes Care, 2017, 40, 777-783
6.2165Citations (PDF)
81Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes
New England Journal of Medicine, 2017, 376, 1507-1516
34.6123Citations (PDF)
82Refining Measurement of Hemoglobin A1c
Clinical Chemistry, 2017, 63, 1433-1435
1.110Citations (PDF)
83Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study
Diabetes Care, 2017, 40, 1010-1016
6.2128Citations (PDF)
84Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
Stroke, 2017, 48, 1218-1225
6.0124Citations (PDF)
85Effect of GLP‐1 and GIP on C‐peptide secretion after glucagon or mixed meal tests: Significance in assessing B‐cell function in diabetes
Diabetes/Metabolism Research and Reviews, 2017, 33,
4.99Citations (PDF)
86Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study
Diabetes Care, 2017, 40, 793-799
6.219Citations (PDF)
87Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care 2017;40:777–783
Diabetes Care, 2017, 40, e165-e166
6.22Citations (PDF)
88Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial
Diabetes Care, 2017, 40, 1763-1770
6.266Citations (PDF)
89Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events
Hypertension, 2017, 70, 907-914
6.613Citations (PDF)
90The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study
Diabetologia, 2017, 60, 2084-2091
7.673Citations (PDF)
91Biomarkers of tubulointerstitial damage and function in type 1 diabetes
BMJ Open Diabetes Research and Care, 2017, 5, e000461
5.413Citations (PDF)
92Pancreatic Safety of Sitagliptin in the TECOS Study
Diabetes Care, 2017, 40, 164-170
6.253Citations (PDF)
93Probabilistic measures of cost‐effectiveness
Statistics in Medicine, 2016, 35, 3976-3986
1.73Citations (PDF)
94Progression of Electrocardiographic Abnormalities in Type 1 Diabetes During 16 Years of Follow‐up: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study
Journal of the American Heart Association, 2016, 5,
4.021Citations (PDF)
95Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME<sup>®</sup>trial
European Heart Journal, 2016, 37, 1526-1534
2.2871Citations (PDF)
96Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus
JAMA Cardiology, 2016, 1, 126
11.2208Citations (PDF)
97Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort
Proceedings of the National Academy of Sciences of the United States of America, 2016, 113,
7.5200Citations (PDF)
98Haptoglobin 2–2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC)
Journal of Diabetes and Its Complications, 2016, 30, 1577-1584
2.421Citations (PDF)
99Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study
Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1969-1977
4.2111Citations (PDF)
100Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes
Cardiovascular Diabetology, 2016, 15,
9.421Citations (PDF)
101Fallacies of last observation carried forward analyses
Clinical Trials, 2016, 13, 161-168
1.8262Citations (PDF)
102Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
New England Journal of Medicine, 2016, 375, 323-334
34.63,297Citations (PDF)
103Large sample inference for a win ratio analysis of a composite outcome based on prioritized components
Biostatistics, 2016, 17, 178-187
2.1110Citations (PDF)
104Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
New England Journal of Medicine, 2016, 374, 1092-1094
34.6257Citations (PDF)
105Significance of Epicardial and Intrathoracic Adipose Tissue Volume among Type 1 Diabetes Patients in the DCCT/EDIC: A Pilot Study
PLoS ONE, 2016, 11, e0159958
2.315Citations (PDF)
106Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes
Cardiovascular Diabetology, 2015, 14,
9.453Citations (PDF)
107Data sharing is desirable, but benefits should not be exaggerated
BMJ, The, 2015, , h5508
0.21Citations (PDF)
108Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
New England Journal of Medicine, 2015, 373, 232-242
34.62,393Citations (PDF)
109Application of the Wei–Lachin multivariate one-directional test to multiple event-time outcomes
Clinical Trials, 2015, 12, 627-633
1.829Citations (PDF)
110Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality
JAMA - Journal of the American Medical Association, 2015, 313, 45
16.6404Citations (PDF)
111Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA<sup>®</sup>)
Diabetes and Vascular Disease Research, 2015, 12, 164-174
2.7203Citations (PDF)
112Intensive Diabetes Therapy and Ocular Surgery in Type 1 Diabetes
New England Journal of Medicine, 2015, 372, 1722-1733
34.6101Citations (PDF)
113Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
New England Journal of Medicine, 2015, 373, 2117-2128
34.610,749Citations (PDF)
114The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes
Journal of Diabetes and Its Complications, 2015, 29, 108-114
2.432Citations (PDF)
115Factors Affecting the Decline in Incidence of Diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS)
Diabetes, 2015, 64, 989-998
4.245Citations (PDF)
116Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients With Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC
Diabetes, 2015, 64, 631-642
4.2306Citations (PDF)
117Applications of the Wei-Lachin Multivariate One-Sided Test for Multiple Outcomes on Possibly Different Scales
PLoS ONE, 2014, 9, e108784
2.335Citations (PDF)
118Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Diabetes Care, 2014, 37, 39-43
6.2188Citations (PDF)
119Methods for a longitudinal quantitative outcome with a multivariate Gaussian distribution multi-dimensionally censored by therapeutic intervention
Statistics in Medicine, 2014, 33, 1288-1306
1.71Citations (PDF)
120Relationship of Glycated Albumin to Blood Glucose and HbA1c Values and to Retinopathy, Nephropathy, and Cardiovascular Outcomes in the DCCT/EDIC Study
Diabetes, 2014, 63, 282-290
4.2204Citations (PDF)
121Evaluating the Role of Epigenetic Histone Modifications in the Metabolic Memory of Type 1 Diabetes
Diabetes, 2014, 63, 1748-1762
4.2228Citations (PDF)
122Longitudinal Changes in Estimated and Measured GFR in Type 1 Diabetes
Journal of the American Society of Nephrology: JASN, 2014, 25, 810-818
0.444Citations (PDF)
123Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial
Diabetes, 2014, 63, 739-748
4.2253Citations (PDF)
124Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria
Journal of the American Society of Nephrology: JASN, 2014, 25, 2342-2350
0.484Citations (PDF)
125Identifying Change Points in a Covariate Effect on Time-to-Event Analysis with Reduced Isotonic Regression
PLoS ONE, 2014, 9, e113948
2.32Citations (PDF)
126Power of the Mantel–Haenszel and other tests for discrete or grouped time‐to‐event data under a chained binomial model
Statistics in Medicine, 2013, 32, 220-229
1.79Citations (PDF)
127Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial
Diabetes and Vascular Disease Research, 2013, 10, 289-301
2.7134Citations (PDF)
128Validity of Self-Report in Type 1 Diabetic Subjects for Laser Treatment of Retinopathy
Ophthalmology, 2013, 120, 2580-2586
7.89Citations (PDF)
129The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes
Journal of Diabetes and Its Complications, 2013, 27, 141-149
2.451Citations (PDF)
130Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata
Statistics in Medicine, 2013, 32, 4413-4425
1.716Citations (PDF)
131Effects of Prior Intensive Versus Conventional Therapy and History of Glycemia on Cardiac Function in Type 1 Diabetes in the DCCT/EDIC
Diabetes, 2013, 62, 3561-3569
4.243Citations (PDF)
132Reminiscences of Jerry Cornfield
Clinical Trials, 2013, 10, 337-339
1.80Citations (PDF)
133Aortic Distensibility in Type 1 Diabetes
Diabetes Care, 2013, 36, 2380-2387
6.223Citations (PDF)
134Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
Diabetes Care, 2013, 36, 2254-2261
6.2238Citations (PDF)
135Haptoglobin Genotype and the Rate of Renal Function Decline in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Diabetes, 2013, 62, 3218-3223
4.238Citations (PDF)
136Circulating Vitamin D Metabolites and Subclinical Atherosclerosis in Type 1 Diabetes
Diabetes Care, 2013, 36, 2423-2429
6.231Citations (PDF)
137Fall in C-Peptide During First 2 Years From Diagnosis
Diabetes, 2012, 61, 2066-2073
4.2303Citations (PDF)
138High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes
Nephrology Dialysis Transplantation, 2012, 27, 1416-1423
0.839Citations (PDF)
139Circulating Vitamin D Metabolites and Kidney Disease in Type 1 Diabetes
Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4780-4788
4.158Citations (PDF)
140Effect of Intensive Glycemic Therapy on Erectile Function in Men With Type 1 Diabetes
Journal of Urology, 2011, 185, 1828-1834
4.283Citations (PDF)
141Effect of rituximab on human in vivo antibody immune responses
Journal of Allergy and Clinical Immunology, 2011, 128, 1295-1302.e5
6.1104Citations (PDF)
142Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes
New England Journal of Medicine, 2011, 365, 2366-2376
34.6548Citations (PDF)
143Levels of Oxidized LDL and Advanced Glycation End Products–Modified LDL in Circulating Immune Complexes Are Strongly Associated With Increased Levels of Carotid Intima-Media Thickness and Its Progression in Type 1 Diabetes
Diabetes, 2011, 60, 582-589
4.291Citations (PDF)
144Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes
Atherosclerosis, 2011, 214, 462-467
1.546Citations (PDF)
145A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants
Pediatric Diabetes, 2011, 12, 85-90
5.512Citations (PDF)
146Power and sample size evaluation for the Cochran–Mantel–Haenszel mean score (Wilcoxon rank sum) test and the Cochran–Armitage test for trend
Statistics in Medicine, 2011, 30, 3057-3066
1.733Citations (PDF)
147Myocardial Structure, Function, and Scar in Patients With Type 1 Diabetes Mellitus
Circulation, 2011, 124, 1737-1746
18.188Citations (PDF)
148Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT
Diabetes, 2011, 60, 1552-1560
4.2239Citations (PDF)
149Determining Stability of Stored Samples Retrospectively: The Validation of Glycated Albumin
Clinical Chemistry, 2011, 57, 286-290
1.155Citations (PDF)
150Progression of Carotid Artery Intima-Media Thickness During 12 Years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study
Diabetes, 2011, 60, 607-613
4.2111Citations (PDF)
151Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and Microalbuminuria&lt;subtitle&gt;An Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort&lt;/subtitle&gt;&lt;alt-title&gt;Microalbuminuria Outcomes in Type 1 Diabetes&lt;/alt-title&gt;
Archives of Internal Medicine, 2011, 171, 412
8.1320Citations (PDF)
152Gaps in the Glycation Gap Hypothesis
Clinical Chemistry, 2011, 57, 150-152
1.129Citations (PDF)
153Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy
Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1032-1040
4.272Citations (PDF)
154Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Type 1 Diabetes
PLoS ONE, 2011, 6, e26471
2.343Citations (PDF)
155DCCT and EDIC Studies in Type 1 Diabetes: Lessons for Diabetic Neuropathy Regarding Metabolic Memory and Natural History
Current Diabetes Reports, 2010, 10, 276-282
5.1119Citations (PDF)
156Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain
Diabetes Care, 2010, 33, 177-183
6.241Citations (PDF)
157Failure to Preserve β-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes
Diabetes Care, 2010, 33, 826-832
6.2153Citations (PDF)
158A Genome-Wide Association Study Identifies a Novel Major Locus for Glycemic Control in Type 1 Diabetes, as Measured by Both A1C and Glucose
Diabetes, 2010, 59, 539-549
4.2109Citations (PDF)
159Point: Intensive Glycemic Control and Mortality in ACCORD—A Chance Finding?
Diabetes Care, 2010, 33, 2719-2721
6.218Citations (PDF)
160Comparison of Urinary Albumin-Creatinine Ratio and Albumin Excretion Rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1235-1242
4.254Citations (PDF)
161Effect of Prior Intensive Insulin Treatment During the Diabetes Control and Complications Trial (DCCT) on Peripheral Neuropathy in Type 1 Diabetes During the Epidemiology of Diabetes Interventions and Complications (EDIC) Study
Diabetes Care, 2010, 33, 1090-1096
6.2342Citations (PDF)
162Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
Journal of Clinical Endocrinology and Metabolism, 2010, 95, 134-142
4.1172Citations (PDF)
163Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial
American Journal of Clinical Nutrition, 2009, 89, 518-524
4.7140Citations (PDF)
164Validity and Reproducibility of Measurement of Islet Autoreactivity by T-Cell Assays in Subjects With Early Type 1 Diabetes
Diabetes, 2009, 58, 2588-2595
4.292Citations (PDF)
165Effects of Prior Intensive Insulin Therapy on Cardiac Autonomic Nervous System Function in Type 1 Diabetes Mellitus
Circulation, 2009, 119, 2886-2893
18.1299Citations (PDF)
166The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results
Pediatric Diabetes, 2009, 10, 97-104
5.5181Citations (PDF)
167Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
New England Journal of Medicine, 2009, 361, 2143-2152
34.61,011Citations (PDF)
168Sample size evaluation for a multiply matched case–control study using the score test from a conditional logistic (discrete Cox PH) regression model
Statistics in Medicine, 2008, 27, 2509-2523
1.754Citations (PDF)
169Type 1 Diabetes TrialNet–An International Collaborative Clinical Trials Network
Annals of the New York Academy of Sciences, 2008, 1150, 14-24
4.0103Citations (PDF)
170Rosiglitazone-Associated Fractures in Type 2 Diabetes
Diabetes Care, 2008, 31, 845-851
6.2521Citations (PDF)
171A Risk Score for Type 1 Diabetes Derived From Autoantibody-Positive Participants in the Diabetes Prevention Trial–Type 1
Diabetes Care, 2008, 31, 528-533
6.2101Citations (PDF)
172Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 Diabetes
Diabetes Care, 2008, 31, 1966-1971
6.2276Citations (PDF)
173Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus
Archives of Internal Medicine, 2008, 168, 1867
8.1110Citations (PDF)
174Prolonged Effect of Intensive Therapy on the Risk of Retinopathy Complications in Patients With Type 1 Diabetes Mellitus
JAMA Ophthalmology, 2008, 126, 1707
2.2320Citations (PDF)
175Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program
Diabetes, 2007, 56, 1153-1159
4.294Citations (PDF)
176A composite design for transition from a preliminary to a full-scale study
Statistics in Medicine, 2007, 26, 5014-5032
1.73Citations (PDF)
177Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
New England Journal of Medicine, 2006, 355, 2427-2443
34.62,837Citations (PDF)
178Operating characteristics of sample size re-estimation with futility stopping based on conditional power
Statistics in Medicine, 2006, 25, 3348-3365
1.715Citations (PDF)
179Parametric survival models for interval-censored data with time-dependent covariates
Biostatistics, 2006, 7, 599-614
2.181Citations (PDF)
180A review of methods for futility stopping based on conditional power
Statistics in Medicine, 2005, 24, 2747-2764
1.7207Citations (PDF)
181Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes
New England Journal of Medicine, 2005, 353, 2643-2653
34.64,660Citations (PDF)
182Maximum information designs
Clinical Trials, 2005, 2, 453-464
1.87Citations (PDF)
183Biological Variation in HbA1c Predicts Risk of Retinopathy and Nephropathy in Type 1 Diabetes: Response to McCarter et al.
Diabetes Care, 2005, 28, 233-233
6.211Citations (PDF)
184The Society for Clinical Trials supports United States legislation mandating trials registration
Clinical Trials, 2004, 1, 417-420
1.87Citations (PDF)
185The role of measurement reliability in clinical trials
Clinical Trials, 2004, 1, 553-566
1.8212Citations (PDF)
186Achieving Weight and Activity Goals Among Diabetes Prevention Program Lifestyle Participants
Obesity, 2004, 12, 1426-1434
4.1488Citations (PDF)
187Conflicts of interest in data monitoring of industry versus publicly financed clinical trials
Statistics in Medicine, 2004, 23, 1519-1521
1.710Citations (PDF)
188A tribute to Samuel W. Greenhouse
Statistics in Medicine, 2003, 22, 3267-3276
1.73Citations (PDF)
189Over-ruling a group sequential boundary?a stopping rule versus a guideline
Statistics in Medicine, 2003, 22, 3347-3355
1.714Citations (PDF)
190Group sequential large sampleT2-like?2 tests for multivariate observations
Statistics in Medicine, 2003, 22, 3357-3368
1.71Citations (PDF)
191Corrections for Bias in Maximum Likelihood Parameter Estimates Due to Nuisance Parameters
Communications in Statistics Part B: Simulation and Computation, 2003, 32, 619-639
1.33Citations (PDF)
192Proatherogenic and Proinflammatory Properties of Immune Complexes Prepared with Purified Human oxLDL Antibodies and Human oxLDL
Clinical Immunology, 2002, 105, 81-92
2.7104Citations (PDF)
193Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin
New England Journal of Medicine, 2002, 346, 393-403
34.617,207Citations (PDF)
194Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy
Diabetologia, 2002, 45, 1562-1571
7.667Citations (PDF)
195Application of robust estimating equations to the analysis of quantitative longitudinal data
Statistics in Medicine, 2001, 20, 3411-3428
1.712Citations (PDF)
196Statistical Considerations in the Intent-to-Treat Principle
Contemporary Clinical Trials, 2000, 21, 167-189
2.8574Citations (PDF)
197A Flexible Stochastic Curtailing Procedure for the Log-Rank Test
Contemporary Clinical Trials, 2000, 21, 428-439
2.813Citations (PDF)
198Statistical Considerations in the Intent-to-Treat Principle
Contemporary Clinical Trials, 2000, 21, 526
2.832Citations (PDF)
199Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy
New England Journal of Medicine, 2000, 342, 381-389
34.61,524Citations (PDF)
200Immunochemical Characterization of Purified Human Oxidized Low-Density Lipoprotein Antibodies
Clinical Immunology, 2000, 95, 135-144
2.761Citations (PDF)
201Worst-Rank Score Analysis with Informatively Missing Observations in Clinical Trials
Contemporary Clinical Trials, 1999, 20, 408-422
2.8145Citations (PDF)
202Antibodies to Oxidized LDL and LDL-Containing Immune Complexes as Risk Factors for Coronary Artery Disease in Diabetes Mellitus
Clinical Immunology, 1999, 90, 165-172
2.7146Citations (PDF)
203GROUP SEQUENTIAL MONITORING OF DISTRIBUTION-FREE ANALYSES OF REPEATED MEASURES
Statistics in Medicine, 1997, 16, 653-668
1.714Citations (PDF)
204The Efficacy of Tolrestat in the Treatment of Diabetic Peripheral Neuropathy: A meta-analysis of individual patient data
Diabetes Care, 1996, 19, 1091-1096
6.228Citations (PDF)
205Distribution-Free Marginal Analysis of Repeated Measures
Drug Information Journal, 1996, 30, 1017-1028
0.08Citations (PDF)
206Martingales without tears
Lifetime Data Analysis, 1995, 1, 361-375
0.84Citations (PDF)
207Nonparametric test of stochastic ordering for multiple longitudinal measures
Journal of Biopharmaceutical Statistics, 1995, 5, 235-243
1.43Citations (PDF)
208Sequential Monitoring of Survival Data with the Wilcoxon Statistic
Biometrics, 1995, 51, 1175
1.623Citations (PDF)
209Natural history and course of acquired lactic acidosis in adults
American Journal of Medicine, 1994, 97, 47-54
2.0199Citations (PDF)
210Use of spending functions for occasional or continuous monitoring of data in clinical trials
Statistics in Medicine, 1993, 12, 2219-2231
1.725Citations (PDF)
211The use of response-adaptive designs in clinical trials
Contemporary Clinical Trials, 1993, 14, 471-484
2.896Citations (PDF)
212A Controlled Clinical Trial of Dichloroacetate for Treatment of Lactic Acidosis in Adults
New England Journal of Medicine, 1992, 327, 1564-1569
34.6327Citations (PDF)
213A Controlled Trial of Plasmapheresis Therapy in Severe Lupus Nephritis
New England Journal of Medicine, 1992, 326, 1373-1379
34.6476Citations (PDF)
214Group Sequential Distribution-Free Methods for the Analysis of Multivariate Observations
Biometrics, 1992, 48, 1033
1.642Citations (PDF)
215Some large‐sample distribution‐free estimators and tests for multivariate partially incomplete data from two populations
Statistics in Medicine, 1992, 11, 1151-1170
1.7108Citations (PDF)
216Power and sample size evaluation for the mcnemar test with application to matched case-control studies
Statistics in Medicine, 1992, 11, 1239-1251
1.760Citations (PDF)
217Termination of a clinical trial with no treatment group difference: The Lupus Nephritis Collaborative Study
Contemporary Clinical Trials, 1992, 13, 62-79
2.826Citations (PDF)
218Implementation of Group Sequential Logrank Tests in a Maximum Duration Trial
Biometrics, 1990, 46, 759
1.672Citations (PDF)
219Permutation tests following restricted randomization procedures
Contemporary Clinical Trials, 1990, 11, 150-152
2.80Citations (PDF)
220Remembrances of Max Halperin
Statistics in Medicine, 1990, 9, 863-870
1.72Citations (PDF)
221Interim analyses with repeated measurements in a sequential clinical trial
Biometrika, 1990, 77, 359-364
2.755Citations (PDF)
222Estimators and Tests in the Analysis of Multiple Nonindependent 2 X 2 Tables with Partially Missing Observations
Biometrics, 1988, 44, 513
1.622Citations (PDF)
223Properties of randomization in clinical trials: Foreword
Contemporary Clinical Trials, 1988, 9, 287-288
2.813Citations (PDF)
224Statistical properties of randomization in clinical trials
Contemporary Clinical Trials, 1988, 9, 289-311
2.8195Citations (PDF)
225Properties of simple randomization in clinical trials
Contemporary Clinical Trials, 1988, 9, 312-326
2.8158Citations (PDF)
226Properties of permuted-block randomization in clinical trials
Contemporary Clinical Trials, 1988, 9, 327-344
2.8279Citations (PDF)
227Properties of the urn randomization in clinical trials
Contemporary Clinical Trials, 1988, 9, 345-364
2.8295Citations (PDF)
228Randomization in clinical trials: Conclusions and recommendations
Contemporary Clinical Trials, 1988, 9, 365-374
2.8245Citations (PDF)
229Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data
Journal of the American Statistical Association, 1988, 83, 339-347
3.4124Citations (PDF)
230Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data
Journal of the American Statistical Association, 1988, 83, 339
3.429Citations (PDF)
231External monitoring of a data coordinating center: Experience of the national cooperative gallstone study
Contemporary Clinical Trials, 1987, 8, 1-11
2.814Citations (PDF)
232Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification
Biometrics, 1986, 42, 507
1.6369Citations (PDF)
233Assessment of stratum-covariate interactions in Cox's proportional hazards regression model
Statistics in Medicine, 1986, 5, 73-83
1.737Citations (PDF)
234Two-Sample Asymptotically Distribution-Free Tests for Incomplete Multivariate Observations
Journal of the American Statistical Association, 1984, 79, 653-661
3.4279Citations (PDF)
235Major issues in the organization and implementation of the national cooperative Gallstone Study (NCGS)
Contemporary Clinical Trials, 1984, 5, 1-12
2.83Citations (PDF)
236Two-Sample Asymptotically Distribution-Free Tests for Incomplete Multivariate Observations
Journal of the American Statistical Association, 1984, 79, 653
3.464Citations (PDF)
237Effects of dose relative to body weight in the national cooperative gallstone study: A fixed-dose trial
Contemporary Clinical Trials, 1983, 4, 125-131
2.83Citations (PDF)
238The National Cooperative Gallstone Study and current management of cholesterol cholelithiasis—Two views
Gastroenterology, 1983, 84, 644-648
0.99Citations (PDF)
239Ultrastructural Evidence of Intrahepatic Cholestasis Before and After Chenodeoxycholic Acid Therapy in Patients With Cholelithiasis: the National Cooperative Gallstone Study
Hepatology, 1983, 3, 209-220
10.132Citations (PDF)
240National Cooperative Gallstone Study
Gastroenterology, 1982, 82, 638-646
0.982Citations (PDF)
241Pretreatment Biliary Lipid Composition in White Patients with Radiol0ucent Gallstones in the National Cooperative Gallstone Study
Gastroenterology, 1982, 83, 738-752
0.9109Citations (PDF)
242A Prospective Morphologic Evaluation of Hepatic Toxicity of Chenodeoxycholic Acid in Patients With Cholelithiasis: the National Cooperative Gallstone Study
Hepatology, 1982, 2, 187S-201S
10.152Citations (PDF)
243Sequential Clinical Trials for Normal Variates Using Interval Composite Hypotheses
Biometrics, 1981, 37, 87
1.612Citations (PDF)
244Introduction to sample size determination and power analysis for clinical trials
Contemporary Clinical Trials, 1981, 2, 93-113
2.8953Citations (PDF)
245Design and methodological considerations in the National Cooperative Gallstone Study: A multicenter clinical trial
Contemporary Clinical Trials, 1981, 2, 177-229
2.852Citations (PDF)
246Perceptions of the coordinating center
Contemporary Clinical Trials, 1980, 1, 125-126
2.81Citations (PDF)
247Sample Size Determinations for r x c Comparative Trials
Biometrics, 1977, 33, 315
1.660Citations (PDF)
248Heart Rate and Blood Pressure in Black Newborns and in White Newborns
Pediatrics, 1976, 58, 283-287
4.512Citations (PDF)
249Phasic Heart Rate Responses: Different Patterns in Black and in White Newborns
Psychosomatic Medicine, 1975, 37, 326-332
2.24Citations (PDF)
250On Stepwise Discriminant Analyses Applied to Physiologic Data
Psychophysiology, 1974, 11, 703-709
2.632Citations (PDF)
251On a Stepwise Procedure for Two Population Bayes Decision Rules Using Discrete Variables
Biometrics, 1973, 29, 551
1.69Citations (PDF)
252Depression as a symptom of alcoholism: Search for a phenomenon.
Journal of Abnormal Psychology, 1968, 73, 195-197
1.955Citations (PDF)
253Title is missing!
0
1Citations (PDF)
254Differences Between Glycemia Estimates from Hemoglobin A1c and Continuous Glucose Monitoring and Their Association with Complete Blood Counts
Diabetes Technology and Therapeutics, 0, ,
4.60Citations (PDF)
255Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
Diabetes Care, 0, 49, 325-334
6.20Citations (PDF)